Article
p27 Expression in Wild-Type KRAS Colon Cancer.
Journal of cellular and molecular medicine - 1 Jun 2026
Marinović Sonja, Paladin Iva, Škrtić Anita, Ivković Tina Catela, Verbanac Donatella, Kapitanović Sanja
Abstract excerpt
p27, a cyclin-dependent kinase inhibitor, functions as a tumour suppressor in the nucleus but may acquire oncogenic properties when mislocalized to the cytoplasm. While KRAS mutations can induce p27 phosphorylation and cytoplasmic retention, the regulation and significance of p27 expression in wild-type (WT) KRAS colorectal cancer (CRC) remain unclear. This study investigated the relationship between WT KRAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
